EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liposomal bupivacaine for sleeve gastrectomy is associated with improved opioid outcomes and lower odds of opioid use disorder: claims-based analysis

Jon Gould, Andras Sandor, Jennifer H Lin, Swapnabir Kakoty, Mary DiGiorgi, Karl A LeBlanc

Surgery for Obesity and Related Diseases · 2025

DOI: 10.1016/j.soard.2024.10.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Surgery for Obesity and Related Diseases, 2025. Verfasst von Jon Gould und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: jgould@mcw.edu. Hauptthemen laut MEDLINE: Bupivacaine, Opioid-Related Disorders, Postoperative Pain, Gastrectomy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pacira BioSciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients undergoing bariatric surgery may be at increased risk for postsurgical opioid dependence, highlighting a need for opioid-sparing anesthesia. OBJECTIVES: Liposomal bupivacaine (LB), a prolonged release formulation of bupivacaine, may improve postoperative pain management and reduce postsurgical opioid use. This retrospective claims-database study investigated the effects of LB versus non-LB analgesia on opioid use and healthcare resource utilization (HCRU) in patients receiving laparoscopic sleeve gastrectomy (SG). SETTING: Retrospective study using the IQVIA linkage claims database. METHODS: Data from patients aged ≥18 years and free of opioid prescriptions within the prior 6 months undergoing inpatient laparoscopic SG between January 1, 2016, and December 31, 2019, were analyzed. Outcomes included perioperative opioid use in oral morphine milligram equivalents (MMEs), opioid-related adverse events (ORAEs), postdischarge HCRU, continued (>2 weeks to 3 months postdischarge) and persistent (4-6 months postdischarge) opioid use, and opioid use disorder (OUD) at 6 months. RESULTS: Of 4298 patients (2149 in each cohort), LB was associated with significantly fewer perioperative opioids (100.53 versus 155.48 MMEs; mean difference, -54.95 [95% confidence interval (CI), -64.46, -45.45]; P < .0001), lower rates of in-hospital ORAEs (9.63% versus 13.82%; odds ratio [OR], .67 [95% CI, .55, .80]; P < .0001), significantly lower incidence of OUD (.09% versus .51%; OR, .18 [95% CI, .04, .82]; P = .026), shorter hospital length of stay (P = .0008), and significantly lower odds of 30-day postdischarge hospital readmissions (P = .025) versus non-LB analgesia. CONCLUSIONS: LB reduced opioid use, in-hospital ORAEs, OUD, and hospital readmissions after laparoscopic SG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BupivacaineOpioid-Related DisordersPostoperative PainGastrectomyAnalgesics, OpioidAnesthetics, LocalBariatric SurgeryHumansFemaleMaleRetrospective StudiesAdultMiddle AgedLaparoscopyLiposomesObesity, Morbid

Stichwörter der Autor:innen

Laparoscopic sleeve gastrectomyLaparoscopic surgeryLiposomal bupivacainePersistent opioid usePostsurgical opioid useSleeve gastrectomy

Substanzen

BupivacaineAnalgesics, OpioidAnesthetics, LocalLiposomes

Autor:innen und Institutionen

  • Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: jgould@mcw.edu.
  • Tufts Medical Center Community Care, Stoneham, Massachusetts.
  • Pacira BioSciences, Inc., Tampa, Florida.
  • Department of Surgery, Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana.

Förderung

  • Pacira BioSciences

Zitieren

APA

Gould, J., Sandor, A., Lin, J. H., Kakoty, S., DiGiorgi, M., & LeBlanc, K. A. (2025). Liposomal bupivacaine for sleeve gastrectomy is associated with improved opioid outcomes and lower odds of opioid use disorder: claims-based analysis. Surgery for Obesity and Related Diseases. https://doi.org/10.1016/j.soard.2024.10.024

Vancouver

Gould J, Sandor A, Lin JH, Kakoty S, DiGiorgi M, LeBlanc KA. Liposomal bupivacaine for sleeve gastrectomy is associated with improved opioid outcomes and lower odds of opioid use disorder: claims-based analysis. Surgery for Obesity and Related Diseases. 2025. doi:10.1016/j.soard.2024.10.024

BibTeX
@article{Gould2025,
  author = {Gould, Jon and Sandor, Andras and Lin, Jennifer H and Kakoty, Swapnabir and DiGiorgi, Mary and LeBlanc, Karl A},
  title = {Liposomal bupivacaine for sleeve gastrectomy is associated with improved opioid outcomes and lower odds of opioid use disorder: claims-based analysis},
  journal = {Surgery for Obesity and Related Diseases},
  year = {2025},
  doi = {10.1016/j.soard.2024.10.024}
}
Kostenlos starten →